MRUS - Merus and myTomorrows expand partnership for eNRGy trial awareness for patients with NRG1 tumors

Merus (MRUS) and myTomorrows, a global health technology company have expanded their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers. Under a 2019 agreement, myTomorrows has been successfully providing support to eligible patients to participate in Merus’ Early Access Program and to receive zenocutuzumab (Zeno, MCLA-128).Expanding the relationship, myTomorrows has agreed to raise awareness of the molecular screening offered by Merus focusing on pancreatic cancer, to identify the presence of NRG1 fusions and to increase awareness of and potential enrollment in Merus’ eNRGy clinical trial.To further support clinical trial options for patients, Merus is offering to cover the cost of performing a full molecular analysis of the patient’s tumor, including DNA and RNA sequencing, by an independent molecular profiling company. Merus is currently enrolling patients on the Phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno

For further details see:

Merus and myTomorrows expand partnership for eNRGy trial awareness for patients with NRG1 tumors